## STUDY AIM

Somatic genetic testing in non-squamous, non-small cell lung carcinoma (NSCLC) patients is required to highlight subgroups eligible for a number of novel oncological therapies. This study aims to determine whether turnaround times for reporting epidermal growth factor receptors (EGFR) by next-generation sequencing (NGS) alone is sufficient to meet the needs of lung cancer patients.

## **STUDY DESIGN**

A retrospective case series with follow-up was performed. Outcomes of EGFR testing (102 tests) in 96 patients by NGS were compared with a rapid, fully automated PCR-based platform (Idylla™) in local histopathology laboratories.

## RESULTS TURNAROUND TIME FROM REQUEST TO REPORT NGS ±23.3 DAYS ±3.8 DAYS IDYLLA™ **CLINICAL IMPACT 6%** of the patient group were **dead before the 18%** of patients experienced rapid clinical deterioration NGS report was available ${f 3}$ of these patients had an actionable variant in EGFR that could have been treated with TKIs. if the NGS report would have been available ANALYTICAL DATA 96.4% agreement between NGS and Idylla™ 82% of failed NGS samples rescued by Idylla™ **10% failure rate** on NGS 5 times less tissue used by Idylla™ compared to NGS in the NSCLC diagnostic workflow

## The right test at the right time to improve patient care and survival outcome.

"We discussed issues around integrating rapid PCR testing alongside NGS in multidisciplinary care pathways and strategies for mitigating against foreseeable difficulties. Dual testing for stage IV non-squamous, NSCLC patients has the potential to improve care and survival outcomes by providing access to the right test at the right time."

Biocartis NV Generaal De Wittelaan 11B 2800 Mechelen, Belgium +32 15 632 888 www.biocartis.com customerservice@biocartis.com Biocartis US, Inc 2 Pierce Place, Suite 1510 Itasca, IL 60143 1-844-443-9552 www.biocartis.com/US customerserviceUS@biocartis.com



Idylla<sup>™</sup> Platform is available as an IVD in Europe, the US and many other countries. Idylla<sup>™</sup> is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative. Biocartis and Idylla<sup>™</sup> are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla<sup>™</sup> trademarks and logos are used trademarks owned by Biocartis. This product is made under a license from SpeeDx Pty Lts. US Patents 8,394,946 and 8,945,836, and pending US applications and all their respective foreign equivalent, supplied under license of SpeeDx Pty Ltd. This product is made under a license from SpeeDx Pty Lts. US Patents 9,506,108, 10,273,526, US 9,963,738 and US 10,724,080 and pending US applications and all their respective foreign equivalent, supplied under license of SpeeDx Pty Ltd. © August 2023, Biocartis NV. All rights reserved.